Is Mankind Pharma the Best Stock in Its Sector? A Look at the Numbers

Is Mankind Pharma the best stock in its sector? The stock trades on the NSE at Rs 2,402 as of 12 October 2026, within its 52-week range of Rs 1,909.70 to Rs 2,642.00. Mankind Pharma Ltd, headquartered in New Delhi, is a pharmaceutical company selling branded generics, consumer healthcare and other products in India.

Mankind Pharma sits in the Healthcare sector, and its 11.74% ROE and 47.32x P/E give a starting point for judging where it stands against comparable listed names. The rest of this article compares those numbers against verified peers and the sector's Industry P/E benchmark.

Also read – Is Abbott India the Best Stock in Its Sector? A Look at the Numbers

Click Here – Get Free Investment Predictions

About Mankind Pharma

Mankind Pharma Ltd, headquartered in New Delhi, is a pharmaceutical company selling branded generics, consumer healthcare and other products in India. Branded generics sold in the domestic market are its main business. The stock trades about 9 percent below its 52-week high and about 26 percent above its 52-week low. At a market capitalisation of Rs 97,850 Cr, it is tracked as part of the Healthcare sector on Univest.

Is Mankind Pharma the Best Stock in Its Sector?

Mankind Pharma's case rests on its domestic branded generics franchise rather than on cheap valuation, with an 11.74% ROE. Its 47.32x P/E is above the 36.69x Industry P/E, and a 6.00 P/B suggests the market already pays up for that franchise.

Metric	Mankind Pharma
CMP (NSE)	Rs 2,402.30
52-Week High / Low	Rs 2,642.00 / Rs 1,909.70
Market Cap	Rs 97,850 Cr
P/E (TTM) vs Industry P/E	47.32x vs 36.69x
P/B	6.00
ROE	11.74%
EPS (TTM)	Rs 50.06
Dividend Yield	0.04%
Debt to Equity	0.39

Compare Mankind Pharma Against Other Healthcare Sector Stocks

How Mankind Pharma Compares Against Its Healthcare Sector Peers

The table below sets Mankind Pharma against 2 other Healthcare sector names, using the same live data source for every company. A peer average row is included for P/E, ROE and debt to equity, calculated across the 2 peer companies.

Company	Market Cap (Rs Cr)	P/E	ROE	Debt to Equity
Mankind Pharma	97,850	47.32	11.74%	0.39
Lupin	89,629	16.15	23.76%	0.29
Alkem Laboratories	62,954	28.56	16.66%	0.15
Peer average (2 companies)	-	22.35	20.21%	0.22

Against this peer set, Mankind Pharma's 11.74% ROE is below the 20.21% peer average, and its P/E of 47.32x runs above the peer average of 22.35x. Its 47.32x P/E is above the 36.69x Industry P/E, and a 6.00 P/B suggests the market already pays up for that franchise.

What Makes Mankind Pharma Worth Watching in Healthcare

• Premium valuation: A 47.32x P/E against a 36.69x Industry P/E means expectations are already built in.
• Moderate returns: An 11.74% ROE is below both pharma peers shown here.
• Moderate leverage: A debt to equity ratio of 0.39 is higher than Lupin and Alkem in the peer table.

Mankind Pharma Valuation: Is It Justified?

Its 47.32x P/E is above the 36.69x Industry P/E, and a 6.00 P/B suggests the market already pays up for that franchise. As with any single stock, investors should weigh this against their own valuation discipline and risk appetite rather than the sector label alone.

Also read – Is Lupin the Best Stock in Its Sector? A Look at the Numbers

Download the Univest iOS App or Univest Android App to track Mankind Pharma and other Healthcare sector stocks.

How to Track Mankind Pharma Before You Invest

Before deciding whether Mankind Pharma deserves its label as the best stock in its sector for your own portfolio, compare it directly against Healthcare sector peers using the steps below.

1. Open the Univest Screener and search for Mankind Pharma to view live price, valuation ratios, and peer comparisons within the Healthcare sector.
2. Compare its P/E, P/B, and ROE against other Healthcare sector stocks before deciding if the current valuation fits your strategy.
3. Set a price alert around key support and resistance zones using the Univest app so you are notified of meaningful moves.
4. Open a broking account on Univest if you decide to add the stock, and size the position based on your own risk appetite and portfolio allocation.

Conclusion

Mankind Pharma earns a place in the best stock in its sector conversation on the strength of an 11.74% ROE and a P/E of 47.32x against a 36.69x Industry P/E, with named peer comparisons in this article backing up that picture. As with any individual stock decision, this analysis is educational and investors should do their own research or consult a SEBI-registered advisor before investing.

Is Mankind Pharma the best stock in its sector?

Ans. Mankind Pharma has an 11.74% ROE and trades at 47.32x P/E against a 36.69x Industry P/E, and compares below the peer average ROE of 20.21% in this article's named comparison, so the answer depends on what an investor is prioritising.

What is the current share price of Mankind Pharma?

Ans. Mankind Pharma was trading at Rs 2,402.30 on the NSE as of 12 October 2026, within its 52-week range of Rs 1,909.70 to Rs 2,642.00.

What sector does Mankind Pharma belong to?

Ans. Mankind Pharma is classified under the Healthcare sector on Univest.

How does Mankind Pharma compare to its sector peers on P/E?

Ans. Mankind Pharma's P/E of 47.32x is above the 22.35x average of the 2 named peers compared in this article.

What is Mankind Pharma's return on equity?

Ans. Mankind Pharma reported a return on equity of 11.74%, which is below the 20.21% average of its named peers in this comparison.

Should I invest in Mankind Pharma based on its sector position?

Ans. Mankind Pharma's sector position and metrics make it worth researching further, but any investment decision should factor in your own risk appetite, its valuation relative to peers, and independent research or advice from a SEBI-registered advisor.